This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. SRPT, BPMC, AXSM, GRFS, NUVL, VRNA, CYTK, ALKS, IONS, and ELANShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Axsome Therapeutics (AXSM), Grifols (GRFS), Nuvalent (NUVL), Verona Pharma (VRNA), Cytokinetics (CYTK), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry. IMARA vs. Sarepta Therapeutics Blueprint Medicines Axsome Therapeutics Grifols Nuvalent Verona Pharma Cytokinetics Alkermes Ionis Pharmaceuticals Elanco Animal Health IMARA (NASDAQ:IMRA) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Do insiders & institutionals believe in IMRA or SRPT? 49.3% of IMARA shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 37.3% of IMARA shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, IMRA or SRPT? IMARA has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Does the media refer more to IMRA or SRPT? In the previous week, Sarepta Therapeutics had 24 more articles in the media than IMARA. MarketBeat recorded 25 mentions for Sarepta Therapeutics and 1 mentions for IMARA. Sarepta Therapeutics' average media sentiment score of 0.72 beat IMARA's score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral Sarepta Therapeutics Positive Do analysts rate IMRA or SRPT? Sarepta Therapeutics has a consensus price target of $158.70, indicating a potential upside of 162.57%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than IMARA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMARA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has higher earnings and valuation, IMRA or SRPT? IMARA has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.051,112.71Sarepta Therapeutics$1.90B3.08-$535.98M$2.2826.51 Is IMRA or SRPT more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to IMARA's net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat IMARA's return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% Sarepta Therapeutics 7.43%11.00%3.35% Does the MarketBeat Community favor IMRA or SRPT? Sarepta Therapeutics received 1446 more outperform votes than IMARA when rated by MarketBeat users. Likewise, 75.03% of users gave Sarepta Therapeutics an outperform vote while only 57.78% of users gave IMARA an outperform vote. CompanyUnderperformOutperformIMARAOutperform Votes2657.78% Underperform Votes1942.22% Sarepta TherapeuticsOutperform Votes147275.03% Underperform Votes49024.97% SummarySarepta Therapeutics beats IMARA on 14 of the 18 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$6.71B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.29%P/E Ratio1,112.937.2322.3918.43Price / SalesN/A239.71391.41101.46Price / Cash75.2465.8538.1834.62Price / Book16.176.306.684.19Net Income$1.49M$143.17M$3.22B$248.05M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$55.64+1.4%N/AN/A$1.46BN/A1,112.9341SRPTSarepta Therapeutics4.6659 of 5 stars$53.90-1.3%$161.83+200.3%-52.6%$5.23B$1.90B43.12840Positive NewsBPMCBlueprint Medicines2.3375 of 5 stars$80.54-2.4%$124.95+55.1%-3.4%$5.15B$508.82M-74.57640Upcoming EarningsNews CoveragePositive NewsAXSMAxsome Therapeutics4.7804 of 5 stars$101.69-1.8%$169.80+67.0%+48.6%$4.96B$385.69M-16.98380Short Interest ↓Positive NewsGRFSGrifols3.8753 of 5 stars$7.13+1.9%N/A+15.0%$4.91B$7.21B6.1026,300Short Interest ↓NUVLNuvalent1.8489 of 5 stars$68.00-2.9%$113.44+66.8%+11.2%$4.87BN/A-19.6040News CoveragePositive NewsVRNAVerona Pharma1.9109 of 5 stars$58.61+1.4%$69.14+18.0%+327.6%$4.74B$42.28M-30.5330Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive NewsCYTKCytokinetics4.1004 of 5 stars$38.77-2.6%$82.00+111.5%-37.6%$4.62B$18.47M-7.21250Analyst ForecastALKSAlkermes4.6253 of 5 stars$27.65+0.4%$38.50+39.2%+13.9%$4.56B$1.56B12.742,280Upcoming EarningsNews CoveragePositive NewsIONSIonis Pharmaceuticals4.0227 of 5 stars$28.44-0.8%$56.72+99.5%-29.0%$4.52B$705.14M-9.35800ELANElanco Animal Health3.8705 of 5 stars$8.47-2.5%$14.67+73.3%-27.5%$4.20B$4.44B21.169,800Short Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies Sarepta Therapeutics Alternatives Blueprint Medicines Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Nuvalent Alternatives Verona Pharma Alternatives Cytokinetics Alternatives Alkermes Alternatives Ionis Pharmaceuticals Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
